Time on treatment with abiraterone and enzalutamide in the patient-overview prostate cancer in the national prostate cancer register of Sweden

Background There are little and inconsistent data from clinical practice on time treatment with the androgen receptor-targeted drugs (ART) abiraterone enzalutamide in men metastatic castration-resistant prostate cancer (mCRPC). We assessed ART investigated predictors of treatment. Material methods Time mCRPC patient-overview (PPC), a subregister National Prostate Cancer Register (NPCR) Sweden, was by use Kaplan-Meier plots Cox regression. To assess representativity PPC for treatment, comparison made all NPCR who had filling Prescribed Drug Registry. Results 2038 received between 2015 2019. Median chemo-naive 10.8 (95% confidence interval 9.1-13.1) months 14.1 (13.5-15.5) enzalutamide. After docetaxel, 8.2 (6.5-12.4) 11.1 (9.8-12.6) Predictors long were duration ADT prior to ART, low serum levels PSA at start absence visceral metastasis, good performance status, no docetaxel. captured 2522/6337 (40%) filled prescription ART. Based fillings Registry, slightly longer median compared NPCR, 9.6 (9.1-10.3) vs. 8.6 (6.3-9.1) months. Conclusions similar or shorter than that published RCTs, due older age, poorer status more comorbidities.